Latest revenue
$3.91B
as of 2026-03-29
Latest net income
$474.0M
as of 2026-03-29
Net margin
12.1%
as of 2026-03-29
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $33.66B
- Enterprise value
- $42.12B
- P/E (trailing)
- 22.9×
- Forward P/E
- —
- P/B
- 3.17×
- Dividend yield
- 4.7%
- 52-wk high
- $24.00
- 52-wk low
- $14.02
- Beta
- —
- Shares out
- 1.92B
5-year trend
What this company does
Kenvue is a consumer health company that sells over-the-counter medicines and personal care products under brands like Tylenol, Listerine, Neutrogena, Band-Aid, and Aveeno. It generates revenue across three segments—Self Care, Skin Health and Beauty, and Essential Health—with nine-month net sales of $11.3 billion, down roughly 4% year-over-year. Kenvue agreed on November 2, 2025 to merge with Kimberly-Clark, ending its short run as an independent company spun out of Johnson & Johnson in 2023.
Generated from KVUE's filing dated 2026-02-20
Key risks
- Pending merger with Kimberly-Clark (announced Nov 2, 2025) creates deal risk: regulatory approval, shareholder vote, and termination-fee exposure dominate near-term outcomes.
- Revenue declining: net sales fell to $11.34B for nine months vs $11.79B prior year (-3.8%); Q3 sales down 3.5% year-over-year.
- Leveraged balance sheet: $7.06B long-term debt plus $1.91B short-term, against only $1.14B cash and $10.6B equity dented by $5.13B accumulated OCI loss.
Generated from KVUE's filing dated 2026-02-20
Profitability
Gross margin
58.1%
0.3%Operating margin
16.0%
34.0%Net margin
9.7%
45.8%Return on equity
13.7%
48.6%Return on assets
5.4%
34.9%Leverage
Debt / equity
1.52×
18.0%Long-term debt / equity
0.69×
Debt / assets
60.2%
7.2%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-29 | $3.91B | +4.5% | $474.0M | +47.2% | 12.1% |
Q4 2025 2025-12-28 | $3.78B | +3.2% | $330.0M | +12.6% | 8.7% |
Q3 2025 2025-09-28 | $3.76B | -3.5% | $398.0M | +3.9% | 10.6% |
Q2 2025 2025-06-29 | $3.84B | -4.0% | $420.0M | +624.1% | 10.9% |
Q1 2025 2025-03-30 | $3.74B | -3.9% | $322.0M | +8.8% | 8.6% |
Q4 2024 2024-12-29 | $3.66B | — | $293.0M | — | 8.0% |
Q3 2024 2024-09-29 | $3.90B | -0.4% | $383.0M | -12.6% | 9.8% |
Q2 2024 2024-06-30 | $4.00B | -0.3% | $58.0M | -86.5% | 1.5% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Perfumes, Cosmetics & Other Toilet Preparations · SIC 2844
Your notes
Keep private notes on KVUE — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$111.0M
Insider selling
$679.7K
Net activity
+$110.3M
Distinct insiders
2
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns KVUE
Institutional value
$12.96B
Total shares held
775.5M
Distinct holders
690
As of
2026-03-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 145.3M | $2.50B | — | New |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 124.4M | $2.15B | — | New |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 92.5M | $1.59B | — | New |
| 4 | DIMENSIONAL FUND ADVISORS LP | 22.3M | $383.9M | — | New |
| 5 | UBS Group AG | 20.8M | $358.0M | — | New |
| 6 | Invesco Ltd. | 18.8M | $323.9M | — | New |
| 7 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 17.5M | $302.0M | — | New |
| 8 | Legal & General Group Plc | 14.4M | $248.0M | — | New |
| 9 | JPMORGAN CHASE & CO | 14.0M | $241.8M | — | New |
| 10 | Nuveen, LLC | 11.5M | $199.1M | — | New |
| 11 | DEUTSCHE BANK AG\ | 11.0M | $189.9M | — | New |
| 12 | Bank of New York Mellon Corp | 10.9M | $187.3M | — | New |
| 13 | VANGUARD FIDUCIARY TRUST CO | 10.8M | $185.9M | — | New |
| 14 | ProShare Advisors LLC | 9.8M | $169.3M | — | New |
| 15 | BANK OF MONTREAL /CAN/ | 9.7M | $166.5M | — | New |
| 16 | YACKTMAN ASSET MANAGEMENT LP | 7.9M | $136.8M | — | New |
| 17 | EQUITY INVESTMENT CORP | 7.6M | $131.6M | — | New |
| 18 | M&G PLC | 7.6M | $128.8M | — | New |
| 19 | Assenagon Asset Management S.A. | 6.4M | $110.4M | — | New |
| 20 | ING GROEP NV | 6.1M | $104.9M | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
- 1
Net sales fell 3.8% YoY to $11.34B for nine months; when does organic growth inflect, and is Neutrogena/Tylenol losing share?
- 2
Restructuring expenses jumped 70% to $204M YTD—quantify total program cost, expected savings, and why this follows last year's $578M impairment.
- 3
Dividends of $1.18B exceeded free cash flow of ~$978M; with $8.97B debt, is the $0.2075 dividend sustainable without releveraging?
Refreshed when KVUE files a new report · last from 2026-02-20